EL7.AI
StocksMediumUpdated•Originally published 14 September 2026•Updated 14 September 2026•
2 min read

FDA Approves Telix’s Pixclara to Distinguish Glioma Progression From Treatment Effects

Key Facts

1The FDA approved Pixclara on September 14, 2026 as a radioactive diagnostic imaging drug, not a cancer treatment.
2The indication covers adults and pediatric patients aged 1 month and older.
3Pixclara is in a Phase 3 registrational study for a potential expansion into diagnosing brain metastases.

Telix Pharmaceuticals said on September 14, 2026 that the US Food and Drug Administration approved Pixclara, or floretyrosine F 18, a radioactive diagnostic drug used with positron emission tomography, or PET, to image gliomas. The product is a diagnostic imaging tool, not a brain cancer treatment.

The indication covers the use of Pixclara with other diagnostic evaluations to distinguish recurrent or progressive glioma from treatment-related change. Approval applies to adults and pediatric patients aged 1 month and older.

Telix said Pixclara is the first FDA-approved FET-PET imaging drug for glioma. The indication addresses a specific post-treatment problem: helping physicians separate tumor activity from changes caused by treatment.

Pixclara comprises a small-molecule targeting compound labeled with the diagnostic radioisotope fluorine-18 and targets the amino-acid transporters LAT1 and LAT2. After administration into the bloodstream, a PET scanner detects energy emissions from the isotope to show areas of uptake.

Pixclara is also in a Phase 3 registrational study for a potential indication expansion into the diagnosis of brain metastases. Telix said the FDA cleared the investigational new drug application for the study to proceed.

For investors, the announcement establishes Pixclara as an approved US product, but it reports neither a move in Telix shares nor a Pixclara revenue forecast. Approval alone therefore does not quantify the financial effect or establish a stock-price direction.

Telix's next announced corporate event is an R&D Day in New York City on September 22, 2026, when the company plans to present a broad overview of its therapeutic and precision-medicine pipelines and related scientific, clinical and strategic developments.